The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer
Abstract
CONTEXT: The association between menopausal hormone replacement therapy and ovarian cancer is unclear. OBJECTIVE: To determine whether hormone replacement therapy using estrogen only, estrogen-progestin only, or both estrogen only and estrogen-progestin increases ovarian cancer risk. DESIGN: A 1979-1998 cohort study of former participants in the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. SETTING: Twenty-nine US clinical centers. PARTICIPANTS: A total of 44 241 postmenopausal women (mean age at start of follow-up, 56.6 years). MAIN OUTCOME MEASURE: Incident ovarian cancer. RESULTS: We identified 329 women who developed ovarian cancer during follow-up. In time-dependent analyses adjusted for age, menopause type, and oral contraceptive use, ever use of estrogen only was significantly associated with ovarian cancer (rate ratio [RR], 1.6; 95% confidence interval [CI], 1.2-2.0). Increasing duration of estrogen-only use was significantly associated with ovarian cancer: RRs for 10 to 19 years and 20 or more years were 1.8 (95% CI, 1.1-3.0) and 3.2 (95% CI, 1.7-5.7), respectively (P value for trend <.001), and we observed a 7% (95% CI, 2%-13%) increase in RR per year of use. We observed significantly elevated RRs with increasing duration of estrogen-only use across all strata of other ovarian cancer risk factors, including women with hysterectomy. The RR for estrogen-progestin use after prior estrogen-only use was 1.5 (95% CI, 0.91-2.4), but the RR for estrogen-progestin-only use was 1.1 (95% CI, 0.64-1.7). The RRs for less than 2 years and 2 or more years of estrogen-progestin-only use were 1.6 (95% CI, 0.78-3.3) and 0.80 (95% CI, 0.35-1.8), respectively, and there was no evidence of a duration response (P value for trend =.30). CONCLUSION: Women who used estrogen-only replacement therapy, particularly for 10 or more years, were at significantly increased risk of ovarian cancer in this study. Women who used short-term estrogen-progestin-only replacement therapy were not at increased risk, but risk associated with short-term and longer-term estrogen-progestin replacement therapy warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk
Schairer, C. (2000) · JAMA · doi:10.1001/jama.283.4.485 · Cited by 1,048
Oral Care Reduces Pneumonia in Older Patients in Nursing Homes
Yoneyama, T., Yoshida, M., Ohrui, T., Mukaiyama, H., Okamoto, H., Hoshiba, K., Ihara, S., Yanagisawa, S., Ariumi, S., Morita, T., et al. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50106.x · Cited by 791
Risch, H. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.23.1774 · Cited by 771
Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women
Rodriguez, C. (2001) · JAMA · doi:10.1001/jama.285.11.1460 · Cited by 424
Persson, I., Yuen, J., Bergkvist, L., & Schairer, C. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960729)67:3<327::aid-ijc4>3.0.co;2-t · Cited by 334
Lau, K.-M., Mok, S. C., & Ho, S.-M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5722 · Cited by 277
Risk of cancer in women receiving hormone replacement therapy
Adami, H., Persson, I., Hoover, R., Schairer, C., & Bergkvist, L. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910440515 · Cited by 267
Risch, H. A., Marrett, L. D., Jain, M., & Howe, G. R. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008937 · Cited by 257
Cited by
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990
Estrogen–gut microbiome axis: Physiological and clinical implications
Baker, J. M., Al-Nakkash, L., & Herbst-Kralovetz, M. M. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.06.025 · Cited by 993
Ovarian cancer and hormone replacement therapy in the Million Women Study
Beral, V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60534-0 · Cited by 937
Ovarian cancer in the world: epidemiology and risk factors
Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019) · International Journal of Women's Health · doi:10.2147/ijwh.s197604 · Cited by 912
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
(2012) · Menopause · doi:10.1097/gme.0b013e31824b970a · Cited by 785
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Rubin, C., Recker, R., Cullen, D., Ryaby, J., McCabe, J., & McLeod, K. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301251 · Cited by 592
Long term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 582
Evidence from randomised trials on the long-term effects of hormone replacement therapy
Beral, V., Banks, E., & Reeves, G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11032-4 · Cited by 487
Loss of ERβ expression as a common step in estrogen-dependent tumor progression
Bardin, A., Boulle, N., Lazennec, G., Vignon, F., & Pujol, P. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00800 · Cited by 417
Albanito, L., Madeo, A., Lappano, R., Vivacqua, A., Rago, V., Carpino, A., Oprea, T. I., Prossnitz, E. R., Musti, A. M., Andò, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2909 · Cited by 399
Hereditary breast and ovarian cancer: new genes in confined pathways
Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.72 · Cited by 367
Gilsanz, V., Wren, T. A., Sanchez, M., Dorey, F., Judex, S., & Rubin, C. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060612 · Cited by 370
Setchell, K. D., & Lydeking-Olsen, E. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.3.593s · Cited by 367
Association of Obesity and Cancer Risk in Canada
Pan, S. Y. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh041 · Cited by 339
Estrogen and skin: The effects of estrogen, menopause, and hormone replacement therapy on the skin
Hall, G., & Phillips, T. J. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.08.039 · Cited by 326
Epidemiology of Ovarian Cancer
Permuth-Wey, J., & Sellers, T. A. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-492-0_20 · Cited by 326
Ovarian Cancer: Etiology, Risk Factors, and Epidemiology
HUNN, J., & RODRIGUEZ, G. C. (2012) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31824b4611 · Cited by 324
Sabbah, M., Emami, S., Redeuilh, G., Julien, S., Prévost, G., Zimber, A., Ouelaa, R., Bracke, M., De Wever, O., & Gespach, C. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.07.001 · Cited by 322
Multiple myeloma: A review of the epidemiologic literature
Alexander, D. D., Mink, P. J., Adami, H.-O., Cole, P., Mandel, J. S., Oken, M. M., & Trichopoulos, D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22718 · Cited by 321
Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses
Lukanova, A., & Kaaks, R. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.98.14.1 · Cited by 314
Estrogen Receptor β: An Overview and Update
Zhao, C., Dahlman-Wright, K., & Gustafsson, J.-Å. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06003 · Cited by 309
Endometriosis and the development of malignant tumours of the pelvis. A review of literature
Van Gorp, T., Amant, F., Neven, P., Vergote, I., & Moerman, P. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2003.03.001 · Cited by 302
Focus on epithelial ovarian cancer
Ozols, R. F., Bookman, M. A., Connolly, D. C., Daly, M. B., Godwin, A. K., Schilder, R. J., Xu, X., & Hamilton, T. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00002-9 · Cited by 294
Dietary n-3 Fatty Acids Decrease Osteoclastogenesis and Loss of Bone Mass in Ovariectomized Mice
Sun, D., Krishnan, A., Zaman, K., Lawrence, R., Bhattacharya, A., & Fernandes, G. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1206 · Cited by 291
The Dioscorea Genus (Yam)—An Appraisal of Nutritional and Therapeutic Potentials
Obidiegwu, J. E., Lyons, J. B., & Chilaka, C. A. (2020) · Foods · doi:10.3390/foods9091304 · Cited by 287
Pathophysiology and Treatment of Hot Flashes
Shanafelt, T. D., Barton, D. L., Adjei, A. A., & Loprinzi, C. L. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.11.1207 · Cited by 273
Estrogen therapy and cognition: a review of the cholinergic hypothesis
Gibbs, R. B. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0036 · Cited by 206
Risks and benefits of dietary isoflavones for cancer
Andres, S., Abraham, K., Appel, K. E., & Lampen, A. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2010.541900 · Cited by 168
Effects of estrogen and progesterone administration on extracellular fluid.
Stachenfeld, N. S., & Taylor, H. S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01032.2003 · Cited by 103
Aromatase excess in cancers of breast, endometrium and ovary
Bulun, S. E., Chen, D., Lu, M., Zhao, H., Cheng, Y., Demura, M., Yilmaz, B., Martin, R., Utsunomiya, H., Thung, S., et al. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.05.027 · Cited by 85
Hot Flashes in Breast Cancer Survivors
Hoda, D., Perez, D. G., & Loprinzi, C. L. (2003) · The Breast Journal · doi:10.1046/j.1524-4741.2003.09526.x · Cited by 35
Patisaul, H., & Whitten, P. (2004) · Endocrine Disruptors · doi:10.1201/9781420038866.ch5 · Cited by 4
Metadata
- Authors
- Lacey, Jr.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-17
- Volume
- 288
- Issue
- 3
- Pages
- 334
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1995055473
- Cited by
- 606
- References
- 34
- FWCI
- 35.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.